Introducing Eveo Cell Therapy Platform
Unlock human-centric manufacturing, accelerating your therapy delivery to patients* with a single platform combining process ownership, maximized usability, and built-in commercial-scale readiness.
Sartorius Eveo Cell Therapy Platform brings together smart automation, quality control, and raw materials for GMP production, empowering cell therapy manufacturers to overcome constraints limiting output.
Sartorius Eveo Cell Therapy Platform is the only closed, user-owned, modular, multi-parallel intensified processing platform designed for multiple cell therapy product types across both centralized and decentralized manufacturing models*.
Ready to get started?
Parallel Processing
Run up to 8 concurrent, unique batches in each Eveo Cell Therapy Workstation.
Achieve > 350 doses per year using only 6 square metres with a single workstation and a single operator.
4 x more productivity per unit floor space vs. conventional manufacturing methods.
Closed, Guided, Automated
Fully closed by design, Eveo Cell Therapy Workstation operates across cleanroom classifications from Grade C / D, ISO 7 / 8 environments, or controlled non-classified spaces.
Eveo Cell Therapy System is engineered to minimize batch-failure rates through online visual guidance and automated liquid path connection, verification and disconnection.
~20% Reduction in Vein-to-Vein Time
Eveo Cell Therapy Platform is compatible with whole blood-based protocols, which minimizes reliance on limited apheresis appointments, while perfusion-enabled cell culture reduces total processing times.
>70%3 Transduction Efficiency
Eveo Cell Therapy Workstation provides high transduction efficiency without the need for transduction enhancers. CAR-T cells also show equivalent quality attributes compared to cells manufactured with traditional methods.
< $35k5 COGS/batch
Benefit from a 90% cost reduction compared to traditional manufacturing processes6, 80% CAPEX reduction and greater operational efficiency.
Run 8 batches in just 6 square metres.
Evolve in 3 ways
Own your processes with a system built for your autonomy.
Craft and deploy your recipes in Eveo Process Manager, independently. Use the Eveo Cell Therapy System modules you need now and change as required. Add workstations to your Eveo network in response to demand.
Deliver now, evolve for the future.
Explore Eveo® Cell Therapy Platform
Click the yellow icons to explore a selection of key features.
Workflow support – Automate your whole process, end to end. Or focus on individual unit operations.
As you need, evolve with Eveo Cell Therapy Platform.
Unlock Real Potential
How Much Could Eveo Cell Therapy Platform Save You?
Connect with our experts to discover how Eveo Cell Therapy Platform can transform your organisation. Using our Cost of Goods Calculator, you will gain clear insights into the benefits of the system in the context of your business.
University College London
“We were pleased to see Sartorius advancing a new GMP manufacturing platform for cell therapies. The system was intuitive and easy to use, enabling rapid translation and improvement of our CAR-T process onto the platform. The platform’s integration of automation, parallelisation and process intensification within a compact footprint offers strong potential to address key scalability bottlenecks in cell therapy manufacturing.”
Prof Qasim Rafiq, Professor in Bioprocess Engineering, Vice Dean (Health) in the Faculty of Engineering Sciences and Director of the UCL Institute of Healthcare Engineering.
Dr Pierre Springuel, Post-doctoral Researcher in Bioprocessing of Cellular Immunotherapies, Dept of Biochemical Engineering.
Built and Sustained by Trusted Professionals8
Backed by deep experience and a team of recognized experts8, we apply automation to streamline biological processes, providing sustained support for development and manufacturing worldwide.
We share your goals to make cell therapy more affordable and accessible for all. With over 150 years of innovation and a commitment to bioprocessing excellence, we are dedicated to your cell therapy success.
Ready to Get Started, or Keen to Stay Informed?
References & Notes
1. Haslam, A. et al. (2024) ‘Estimation of eligibility for and response to CAR T therapy in the US’, Blood Advances, 8(4), pp. 1032–1036.
2. Mikhael, J., Fowler, J. and Shah, N. (2022) ‘Chimeric antigen receptor T cell therapies: Barriers and solutions to access’, JCO Oncology Practice, 18(11), pp. e1641–e1650.
3. Springuel, P. (2025) Removing barriers to sustainable autologous therapies. Presented at: Sartorius CGT Forum, October 2025.
4. Hu, B., Vaidya, R., Ahmed, F., Ehsan, H., Moyo, T.K., Jacobs, R.W. et al. (2024) ‘Real world analysis of barriers to timely administration of chimeric antigen receptor T cell therapy in diffuse large B cell lymphoma’, Transplantation and Cellular Therapy, 11 September. PMID: 39270935.
5. Partopour, B., Pollard, D. and Binninger, S. (2025) ‘Minimizing cost of goods in autologous cell therapy using a new fully automated, closed, optimized throughput manufacturing platform’, Cytotherapy, 27(5 Suppl), p. S153.
6. Alliance for Regenerative Medicine (2026) Reasons to Believe: Innovation, Access & Sustainability in CGT. Washington, DC: ARM. Available at: https://alliancerm.org/wp-content/uploads/2026/01/ARM-CGT-Reasons-to-Believe-January-26-2026.pdf
7. Ran, T., Eichmüller, S.B., Schmidt, P. and Schlander, M. (2020) ‘Cost of decentralized CAR T cell production in an academic non-profit setting’, International Journal of Cancer, 147(6), pp. 1768–1778. doi:10.1002/ijc.33156.
8. ESACT (2022) Innovation Award 2022. Available at: https://esact.org/activities/innovation-award/
*The Eveo Cell Therapy platform is for manufacturing use only. Any clinical application of the target cells is exclusively within the responsibility of the user.